董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Burell | 男 | Director | 61 | 16.06万美元 | 0.25 | 2026-03-24 |
| Harel Gadot | 男 | Chairman of the Board and Chief Executive Officer and President | 54 | 166.49万美元 | 32.98 | 2026-03-24 |
| Martin Madden | 男 | Director | 65 | 16.06万美元 | 0.25 | 2026-03-24 |
| Prattipati Laxminarain | 男 | Director | 68 | 13.43万美元 | 0.25 | 2026-03-24 |
| Aileen Stockburger | 女 | Director | 63 | 13.01万美元 | 未持股 | 2026-03-24 |
| Tal Wenderow | 男 | Director | 51 | 12.56万美元 | 未持股 | 2026-03-24 |
| David J. Wilson | 男 | Director | 58 | 8.20万美元 | 未持股 | 2026-03-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harel Gadot | 男 | Chairman of the Board and Chief Executive Officer and President | 54 | 166.49万美元 | 32.98 | 2026-03-24 |
| Simon Sharon | 男 | Chief Technology Officer and General Manager, Microbot Israel | 66 | 59.65万美元 | 未持股 | 2026-03-24 |
| Rachel Vaknin | 女 | Chief Financial Officer | 47 | 44.00万美元 | 未持股 | 2026-03-24 |
| Juan Diaz Cartelle | 男 | Chief Medical Officer | 50 | 53.19万美元 | 未持股 | 2026-03-24 |
董事简历
中英对照 | 中文 | 英文- Scott Burell
-
Scott Burell在合并后成为Microbot Medical Inc.的董事。自2018年8月1日起，Burell先生一直担任AIVITA Biomedical，Inc.的首席财务官。AIVITA Biomedical，Inc.是一家总部位于加利福尼亚州欧文市的免疫肿瘤公司，专注于利用治疗和再生药物推进商业和临床阶段计划。从2006年11月到2017年11月出售给因维塔公司（NYSE：NVTA），他是CombiMatrix Corporation（NASDAQ：CBMX）的首席财务官、秘书和财务主管。CombiMatrix Corporation是一家专注于家庭健康的临床分子诊断实验室，专门从事植入前基因筛查、产前诊断、流产分析，和儿童发育障碍。2007年，他成功地领导了CombiMatrix与其前母公司的分拆，并领导了几次成功的公共和私人债务及股权融资交易，以及CombiMatrix在2010年的重组。在此之前，Burell先生自2001年11月起担任CombiMatrix的财务副总裁，并于2001年2月至2001年11月担任其财务总监。从1999年5月至2001年2月首次加入CombiMatrix，Burell先生担任Network Commerce，Inc.（纳斯达克：SPNW）的财务总监，位于西雅图的一家公开交易的技术和信息基础设施公司。在此之前，Burell先生在西雅图安达信审计和商业咨询事务所工作了九年。在担任公共会计期间，Burell先生在高科技和医疗市场与许多公共和私人客户合作，并参与了大量公开发行、分拆、合并和收购。Burell先生于1992年获得华盛顿州注册会计师执照，是一名注册会计师（目前不在职）。他拥有中央华盛顿大学会计和商业金融学理学学士学位。
Scott Burell became a director of the Company in November 2016. Since Augt 2018, Mr. Burell has been the Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an Irvine California based immuno oncology company foced on the advancement of commercial and clinical stage programs utilizing curative and regenerative medicines. In October 2025, Mr. Burell was appointed to the Board of Directors of Expion360 (Nasdaq: XPON), an indtry leader of premium lithium iron phosphate batteries and accessories for recreational vehicles and marine applications, with residential and indtrial applications under development. From November 2006 until its sale to Invitae Corp. (NASDAQ: NVTA) in November 2017, he was the Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX), a family health foced clinical molecular diagnostic laboratory specializing in pre implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. He successfully led the split off of CombiMatrix in 2007 from its former parent, has led several successful public and private debt and equity financing transactions as ll as CombiMatrix's reorganization in 2010. Prior to this, Mr. Burell had served as CombiMatrix's Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001. From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc. (NASDAQ: SPNW), a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen's Audit and Biness Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high tech and healthcare markets, and was involved in numero public offerings, spin offs, mergers and acquisitions. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive). He holds Bachelor of Science degrees in Accounting and Biness Finance from Central Washington University. - Scott Burell在合并后成为Microbot Medical Inc.的董事。自2018年8月1日起，Burell先生一直担任AIVITA Biomedical，Inc.的首席财务官。AIVITA Biomedical，Inc.是一家总部位于加利福尼亚州欧文市的免疫肿瘤公司，专注于利用治疗和再生药物推进商业和临床阶段计划。从2006年11月到2017年11月出售给因维塔公司（NYSE：NVTA），他是CombiMatrix Corporation（NASDAQ：CBMX）的首席财务官、秘书和财务主管。CombiMatrix Corporation是一家专注于家庭健康的临床分子诊断实验室，专门从事植入前基因筛查、产前诊断、流产分析，和儿童发育障碍。2007年，他成功地领导了CombiMatrix与其前母公司的分拆，并领导了几次成功的公共和私人债务及股权融资交易，以及CombiMatrix在2010年的重组。在此之前，Burell先生自2001年11月起担任CombiMatrix的财务副总裁，并于2001年2月至2001年11月担任其财务总监。从1999年5月至2001年2月首次加入CombiMatrix，Burell先生担任Network Commerce，Inc.（纳斯达克：SPNW）的财务总监，位于西雅图的一家公开交易的技术和信息基础设施公司。在此之前，Burell先生在西雅图安达信审计和商业咨询事务所工作了九年。在担任公共会计期间，Burell先生在高科技和医疗市场与许多公共和私人客户合作，并参与了大量公开发行、分拆、合并和收购。Burell先生于1992年获得华盛顿州注册会计师执照，是一名注册会计师（目前不在职）。他拥有中央华盛顿大学会计和商业金融学理学学士学位。
- Scott Burell became a director of the Company in November 2016. Since Augt 2018, Mr. Burell has been the Chief Financial Officer and Secretary of AIVITA Biomedical, Inc., an Irvine California based immuno oncology company foced on the advancement of commercial and clinical stage programs utilizing curative and regenerative medicines. In October 2025, Mr. Burell was appointed to the Board of Directors of Expion360 (Nasdaq: XPON), an indtry leader of premium lithium iron phosphate batteries and accessories for recreational vehicles and marine applications, with residential and indtrial applications under development. From November 2006 until its sale to Invitae Corp. (NASDAQ: NVTA) in November 2017, he was the Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQ: CBMX), a family health foced clinical molecular diagnostic laboratory specializing in pre implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. He successfully led the split off of CombiMatrix in 2007 from its former parent, has led several successful public and private debt and equity financing transactions as ll as CombiMatrix's reorganization in 2010. Prior to this, Mr. Burell had served as CombiMatrix's Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001. From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc. (NASDAQ: SPNW), a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen's Audit and Biness Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high tech and healthcare markets, and was involved in numero public offerings, spin offs, mergers and acquisitions. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive). He holds Bachelor of Science degrees in Accounting and Biness Finance from Central Washington University.
- Harel Gadot
-
Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
Harel Gadot is a co founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He also serves as a director from September 2025 of Brenmiller Energy (NASDAQ: BNRG). He has been the Chairman of Microbot Israel's board of directors since July 2014. He also served as a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel, and was its Chairman from Augt 2013 until September 2023. Mr. Gadot served as Chairman of MEDX Xelerator L.P., a medical device and digital health Israeli incubator, from July 2016 until Augt 2025. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as ll as leading regional strategic position for Europe, Middle East and Africa, as ll as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from Augt 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly Clark Corporation. Mr. Gadot holds a B.Sc. in Biness from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK. - Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
- Harel Gadot is a co founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He also serves as a director from September 2025 of Brenmiller Energy (NASDAQ: BNRG). He has been the Chairman of Microbot Israel's board of directors since July 2014. He also served as a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel, and was its Chairman from Augt 2013 until September 2023. Mr. Gadot served as Chairman of MEDX Xelerator L.P., a medical device and digital health Israeli incubator, from July 2016 until Augt 2025. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as ll as leading regional strategic position for Europe, Middle East and Africa, as ll as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from Augt 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly Clark Corporation. Mr. Gadot holds a B.Sc. in Biness from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.
- Martin Madden
-
Martin Madden，自2017年2月6日起担任公司董事。Madden先生曾于1986年至2017年1月在强生公司及其关联公司担任多个职位，最近于2016年2月至2017年1月担任强生公司公司DePuy Synthes研发Vice President。在此之前，从2015年7月至2016年2月，马登先生是强生公司医疗设备公司的Vice President兼新产品开发。2012年1月至2015年7月，马登先生是强生公司全球外科集团的研发Vice President。Madden先生拥有哥伦比亚大学（Columbia University）工商管理硕士学位，卡内基梅隆大学（Carnegie Mellon University）机械工程硕士学位，以及代顿大学（University of Dayton）机械工程学士学位。
Martin Madden has been a director of the Company since February 6, 2017. Mr. Madden has held vario positions at Johnson & Johnson and its affiliates from 1986 to January 2017, most recently as Vice President, Research & Development of DePuy Synthes, a Johnson & Johnson Company, from February 2016 to January 2017. Prior to that, from July 2015 to February 2016, Mr. Madden was the Vice President, New Product Development of Johnson & Johnson Medical Devices. From January 2012 to July 2015, Mr. Madden was the Vice President, Research & Development of Johnson & Johnson's Global Surgery Group. During his thirty year tenure with Johnson & Johnson's Medical Device organization, he was an innovator and research leader for nearly every medical device biness including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an executive of Johnson & Johnson, Mr. Madden served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo Surgery, DePuy Synthes, and Cordis, with responsibility for research and development inclive of organic and licensed/acquired technology. He was also Chairman of J&J's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Mr. Madden serves on the Board of Directors of Novocure (NASDAQ: NVCR), a global oncology company, and is an advisor to numero medical device start ups. Mr. Madden holds a MBA from Columbia University, a M.S. from Carnegie Mellon University in Mechanical Engineering, and a B.S. from the University of Dayton in Mechanical Engineering. - Martin Madden，自2017年2月6日起担任公司董事。Madden先生曾于1986年至2017年1月在强生公司及其关联公司担任多个职位，最近于2016年2月至2017年1月担任强生公司公司DePuy Synthes研发Vice President。在此之前，从2015年7月至2016年2月，马登先生是强生公司医疗设备公司的Vice President兼新产品开发。2012年1月至2015年7月，马登先生是强生公司全球外科集团的研发Vice President。Madden先生拥有哥伦比亚大学（Columbia University）工商管理硕士学位，卡内基梅隆大学（Carnegie Mellon University）机械工程硕士学位，以及代顿大学（University of Dayton）机械工程学士学位。
- Martin Madden has been a director of the Company since February 6, 2017. Mr. Madden has held vario positions at Johnson & Johnson and its affiliates from 1986 to January 2017, most recently as Vice President, Research & Development of DePuy Synthes, a Johnson & Johnson Company, from February 2016 to January 2017. Prior to that, from July 2015 to February 2016, Mr. Madden was the Vice President, New Product Development of Johnson & Johnson Medical Devices. From January 2012 to July 2015, Mr. Madden was the Vice President, Research & Development of Johnson & Johnson's Global Surgery Group. During his thirty year tenure with Johnson & Johnson's Medical Device organization, he was an innovator and research leader for nearly every medical device biness including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. As an executive of Johnson & Johnson, Mr. Madden served on the management boards of Johnson & Johnson's Global Surgery Group, Ethicon, Ethicon Endo Surgery, DePuy Synthes, and Cordis, with responsibility for research and development inclive of organic and licensed/acquired technology. He was also Chairman of J&J's Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Mr. Madden serves on the Board of Directors of Novocure (NASDAQ: NVCR), a global oncology company, and is an advisor to numero medical device start ups. Mr. Madden holds a MBA from Columbia University, a M.S. from Carnegie Mellon University in Mechanical Engineering, and a B.S. from the University of Dayton in Mechanical Engineering.
- Prattipati Laxminarain
-
Prattipati Laxminarain，自2017年12月6日起担任公司董事。从2006年4月至2017年10月，Laxminarain先生担任Codman Neuro的全球总裁，Codman Neuro是一家全球神经外科和神经血管公司，提供脑积水管理，神经重症监护和颅骨手术及其他技术的设备组合，它是强生公司DePuy合成公司的一部分。Laxminarain先生目前是Deinde Medical Corporation的首席执行官，并且是Oculogica Inc.、Millar Inc.和GT Medical Inc.的董事会成员。他获有印度海德拉巴Osmania University的机械工程学位，以及Indian Institute of Management的工商管理硕士学位。
Prattipati Laxminarain has been a director of the Company since December 6, 2017. From April 2006 through October 2017, Mr. Laxminarain served as Worldwide President at Codman Neuro, a global neurosurgery and neurovascular company that offers a portfolio of devices for hydrocephal management, neuro intensive care and cranial surgery and other technologies, and which was part of DePuy Synthes Companies of Johnson & Johnson. Mr. Laxminarain was the CEO of Deinde Medical Corporation through June 2025, and is a Board Member of Deinde Medical Corporation, Oculogica Inc., Millar Inc., and GT Medical Inc. He has a degree in Mechanical Engineering from Osmania University, Hyderabad, India and an MBA from Indian Institute of Management. - Prattipati Laxminarain，自2017年12月6日起担任公司董事。从2006年4月至2017年10月，Laxminarain先生担任Codman Neuro的全球总裁，Codman Neuro是一家全球神经外科和神经血管公司，提供脑积水管理，神经重症监护和颅骨手术及其他技术的设备组合，它是强生公司DePuy合成公司的一部分。Laxminarain先生目前是Deinde Medical Corporation的首席执行官，并且是Oculogica Inc.、Millar Inc.和GT Medical Inc.的董事会成员。他获有印度海德拉巴Osmania University的机械工程学位，以及Indian Institute of Management的工商管理硕士学位。
- Prattipati Laxminarain has been a director of the Company since December 6, 2017. From April 2006 through October 2017, Mr. Laxminarain served as Worldwide President at Codman Neuro, a global neurosurgery and neurovascular company that offers a portfolio of devices for hydrocephal management, neuro intensive care and cranial surgery and other technologies, and which was part of DePuy Synthes Companies of Johnson & Johnson. Mr. Laxminarain was the CEO of Deinde Medical Corporation through June 2025, and is a Board Member of Deinde Medical Corporation, Oculogica Inc., Millar Inc., and GT Medical Inc. He has a degree in Mechanical Engineering from Osmania University, Hyderabad, India and an MBA from Indian Institute of Management.
- Aileen Stockburger
-
艾琳·斯托克伯格（Aileen Stockburger）于2020年3月26日被董事会任命为董事会成员，以填补董事会空缺并担任公司II类董事，任期自2020年4月1日开始。自2018年2月起，Stockburger女士通过Aileen Stockburger LLC提供并购咨询和咨询服务。在此之前，从1989年到2018年1月，斯托克伯格女士在强生公司担任过多个职位，最近的职位是担任强生公司DePuy Synthes Group的Vice President，负责全球业务发展和战略规划，并担任其全球董事会和集团运营委员会的成员，从2010年到2018年。在该职位上，她监督集团的并购活动，包括交易结构，谈判，合同设计和审查以及交易条款。在加入强生公司之前，斯托克伯格女士在普华永道会计师事务所（PricewaterhouseCoopers）工作了几年，并获得了注册会计师证书。她也是Next Science Limited ASX:NXS的非执行董事，这是一家总部位于澳大利亚悉尼的医疗技术公司，主要专注于其专有技术的开发和持续商业化，以减少基于生物膜的感染对人类健康的影响。Stockburger女士在宾夕法尼亚大学沃顿商学院（Wharton School，University of Pennsylvania）获得工商管理硕士学位和学士学位。
Aileen Stockburger has provided M&A consulting and advisory services through Aileen Stockburger LLC. Prior to that, from 1989 through January 2018, Ms. Stockburger held vario positions in Johnson & Johnson, most recently as Vice President, Worldwide Biness Development & Strategic Planning for the DePuy Synthes Group of Johnson & Johnson, and as a member of its Worldwide Board and Group Operating Committee, from 2010 2018. In that role, she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Before joining Johnson & Johnson, Ms. Stockburger spent several years at PriceWaterhoeCoopers, and earned her CPA certification. She is also the Chair of Next Science Limited (ASX: NXS), a medical technology company headquartered in Sydney, Atralia, with a primary foc in the development and continued commercialization of its proprietary technology to reduce the impact of biofilm based infections in human health. She also serve on the Audit Committee and the People, Culture and Remuneration Committee of the Board of Directors of Next Science Limited. Ms. Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania. - 艾琳·斯托克伯格（Aileen Stockburger）于2020年3月26日被董事会任命为董事会成员，以填补董事会空缺并担任公司II类董事，任期自2020年4月1日开始。自2018年2月起，Stockburger女士通过Aileen Stockburger LLC提供并购咨询和咨询服务。在此之前，从1989年到2018年1月，斯托克伯格女士在强生公司担任过多个职位，最近的职位是担任强生公司DePuy Synthes Group的Vice President，负责全球业务发展和战略规划，并担任其全球董事会和集团运营委员会的成员，从2010年到2018年。在该职位上，她监督集团的并购活动，包括交易结构，谈判，合同设计和审查以及交易条款。在加入强生公司之前，斯托克伯格女士在普华永道会计师事务所（PricewaterhouseCoopers）工作了几年，并获得了注册会计师证书。她也是Next Science Limited ASX:NXS的非执行董事，这是一家总部位于澳大利亚悉尼的医疗技术公司，主要专注于其专有技术的开发和持续商业化，以减少基于生物膜的感染对人类健康的影响。Stockburger女士在宾夕法尼亚大学沃顿商学院（Wharton School，University of Pennsylvania）获得工商管理硕士学位和学士学位。
- Aileen Stockburger has provided M&A consulting and advisory services through Aileen Stockburger LLC. Prior to that, from 1989 through January 2018, Ms. Stockburger held vario positions in Johnson & Johnson, most recently as Vice President, Worldwide Biness Development & Strategic Planning for the DePuy Synthes Group of Johnson & Johnson, and as a member of its Worldwide Board and Group Operating Committee, from 2010 2018. In that role, she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Before joining Johnson & Johnson, Ms. Stockburger spent several years at PriceWaterhoeCoopers, and earned her CPA certification. She is also the Chair of Next Science Limited (ASX: NXS), a medical technology company headquartered in Sydney, Atralia, with a primary foc in the development and continued commercialization of its proprietary technology to reduce the impact of biofilm based infections in human health. She also serve on the Audit Committee and the People, Culture and Remuneration Committee of the Board of Directors of Next Science Limited. Ms. Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania.
- Tal Wenderow
-
Tal Wenderow于2020年7月29日由董事会任命，以填补董事会空缺并担任公司的I类董事，任期自2020年8月1日开始。自2019年2月起，Wenderow先生担任Vocalis Health Inc.的总裁兼首席执行官，该公司是一家AI HealthTech公司，致力于开发声乐生物标志物。此前，Wenderow先生于2002年共同创立了Corindus Vascular Robotics，该公司于2019年被Siemens Healthineers收购，是一家纽约证券交易所上市公司。Wenderow先生曾在Corindus担任多个职位，从创始人、首席执行官和成立之初的董事、执行Vice President产品和业务开发，到最近担任国际和业务开发执行Vice President。Wenderow先生获得工商管理学士学位。以色列海法Technion-Israel Institute of Technology机械工程学位。
Tal Wenderow became the Founding Managing Partner of Star51 Capital, a new investment vehicle foced on the intersection of Medtech & AI. From June 2024 to December 2024, Mr. nderow served as interim CEO of Sensory Cloud Inc., a health technology company pioneering treatments for respiratory human illnesses of the airway lining. Since September 2021, Mr. nderow serves as the Venture Partner at Genesis MedTech, a global medical device company. Previoly, from February 2019, Mr. nderow served as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Previoly, Mr. nderow co founded Corind Vascular Robotics in 2002, which was a New York Stock Exchange listed company upon its acquisition by Siemens Healthineers in 2019. Mr. nderow held vario positions at Corind from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Biness Development to his most recent role as Executive Vice President of International & Biness Development. Mr. nderow received a B.Sc. in Mechanical Engineering at the Technion Israel Institute of Technology, Haifa, Israel. - Tal Wenderow于2020年7月29日由董事会任命，以填补董事会空缺并担任公司的I类董事，任期自2020年8月1日开始。自2019年2月起，Wenderow先生担任Vocalis Health Inc.的总裁兼首席执行官，该公司是一家AI HealthTech公司，致力于开发声乐生物标志物。此前，Wenderow先生于2002年共同创立了Corindus Vascular Robotics，该公司于2019年被Siemens Healthineers收购，是一家纽约证券交易所上市公司。Wenderow先生曾在Corindus担任多个职位，从创始人、首席执行官和成立之初的董事、执行Vice President产品和业务开发，到最近担任国际和业务开发执行Vice President。Wenderow先生获得工商管理学士学位。以色列海法Technion-Israel Institute of Technology机械工程学位。
- Tal Wenderow became the Founding Managing Partner of Star51 Capital, a new investment vehicle foced on the intersection of Medtech & AI. From June 2024 to December 2024, Mr. nderow served as interim CEO of Sensory Cloud Inc., a health technology company pioneering treatments for respiratory human illnesses of the airway lining. Since September 2021, Mr. nderow serves as the Venture Partner at Genesis MedTech, a global medical device company. Previoly, from February 2019, Mr. nderow served as the President and CEO of Vocalis Health Inc., an AI healthtech company pioneering the development of vocal biomarkers. Previoly, Mr. nderow co founded Corind Vascular Robotics in 2002, which was a New York Stock Exchange listed company upon its acquisition by Siemens Healthineers in 2019. Mr. nderow held vario positions at Corind from founder, Chief Executive Officer and director at inception, Executive Vice President Product & Biness Development to his most recent role as Executive Vice President of International & Biness Development. Mr. nderow received a B.Sc. in Mechanical Engineering at the Technion Israel Institute of Technology, Haifa, Israel.
- David J. Wilson
-
David J. Wilson一直担任InnovHeart Corporation的首席执行官和董事，该公司是一家开发经导管二尖瓣置换系统以治疗患有二尖瓣疾病的患者的私营公司。2017年9月至2021年10月，他在Haemonetics Corporation担任全球血浆总裁，领导了下一代血浆采集系统的全球商业化。他奉献了二十年的时间，在与vario Johnson and Johnson（J & J）公司一起承担越来越多的责任，包括担任Cordis的全球总裁。在担任这一职务期间，他领导了Cordis在全球范围内融入卡地纳健康，并通过BINCE开发交易使产品组合重新焕发活力。Wilson先生在强生公司担任过其他领导职务，即Mentor总裁、Ethicon研发副总裁和Ethicon Biosurgicals副总裁。在强生任职的早期，他曾在Cordis Endovascular担任高级领导职务，担任研发副总裁和区域销售总监。Wilson先生目前担任阿拉巴马大学伯明翰工程学院工程咨询委员会成员（主席）。他是10项医疗器械专利的持有人，曾担任美国多家教育和医疗保健机构的董事会成员。他的教育包括奥本大学机械工程学士学位、阿拉巴马大学伯明翰分校生物医学工程理学硕士学位和哥伦比亚大学BINCE Administration硕士学位。
David J. Wilson has been the Chief Executive Officer and a director of InnovHeart Corporation, a private company developing transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease. From September 2017 to October 2021, he was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. He dedicated two decades in roles of increasing responsibility with vario Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. In this role, he led the global integration of Cordis into Cardinal Health and rejuvenated the product portfolio through biness development deals. Mr. Wilson held other leadership roles at J&J companies, namely President of Mentor, Vice President of Ethicon R&D and Vice President of Ethicon Biosurgicals. Earlier in his tenure with J&J, he attained senior leadership roles at Cordis Endovascular as Vice President of R&D and Regional Director of Sales. Mr. Wilson currently serves as an Engineering Advisory Board member (Chair) for the University of Alabama at Birmingham School of Engineering. He is the holder of 10 medical device patents and has served as a Board member of several educational and healthcare institutions in the . His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Biness Administration from Columbia University. - David J. Wilson一直担任InnovHeart Corporation的首席执行官和董事，该公司是一家开发经导管二尖瓣置换系统以治疗患有二尖瓣疾病的患者的私营公司。2017年9月至2021年10月，他在Haemonetics Corporation担任全球血浆总裁，领导了下一代血浆采集系统的全球商业化。他奉献了二十年的时间，在与vario Johnson and Johnson（J & J）公司一起承担越来越多的责任，包括担任Cordis的全球总裁。在担任这一职务期间，他领导了Cordis在全球范围内融入卡地纳健康，并通过BINCE开发交易使产品组合重新焕发活力。Wilson先生在强生公司担任过其他领导职务，即Mentor总裁、Ethicon研发副总裁和Ethicon Biosurgicals副总裁。在强生任职的早期，他曾在Cordis Endovascular担任高级领导职务，担任研发副总裁和区域销售总监。Wilson先生目前担任阿拉巴马大学伯明翰工程学院工程咨询委员会成员（主席）。他是10项医疗器械专利的持有人，曾担任美国多家教育和医疗保健机构的董事会成员。他的教育包括奥本大学机械工程学士学位、阿拉巴马大学伯明翰分校生物医学工程理学硕士学位和哥伦比亚大学BINCE Administration硕士学位。
- David J. Wilson has been the Chief Executive Officer and a director of InnovHeart Corporation, a private company developing transcatheter mitral valve replacement systems to treat patients suffering from mitral valve disease. From September 2017 to October 2021, he was the President of Global Plasma at Haemonetics Corporation where he led the global commercialization of a next generation plasma collection system. He dedicated two decades in roles of increasing responsibility with vario Johnson and Johnson (J&J) companies, including as the Worldwide President of Cordis. In this role, he led the global integration of Cordis into Cardinal Health and rejuvenated the product portfolio through biness development deals. Mr. Wilson held other leadership roles at J&J companies, namely President of Mentor, Vice President of Ethicon R&D and Vice President of Ethicon Biosurgicals. Earlier in his tenure with J&J, he attained senior leadership roles at Cordis Endovascular as Vice President of R&D and Regional Director of Sales. Mr. Wilson currently serves as an Engineering Advisory Board member (Chair) for the University of Alabama at Birmingham School of Engineering. He is the holder of 10 medical device patents and has served as a Board member of several educational and healthcare institutions in the . His education includes a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Biness Administration from Columbia University.
高管简历
中英对照 | 中文 | 英文- Harel Gadot
Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
Harel Gadot is a co founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He also serves as a director from September 2025 of Brenmiller Energy (NASDAQ: BNRG). He has been the Chairman of Microbot Israel's board of directors since July 2014. He also served as a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel, and was its Chairman from Augt 2013 until September 2023. Mr. Gadot served as Chairman of MEDX Xelerator L.P., a medical device and digital health Israeli incubator, from July 2016 until Augt 2025. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as ll as leading regional strategic position for Europe, Middle East and Africa, as ll as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from Augt 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly Clark Corporation. Mr. Gadot holds a B.Sc. in Biness from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.- Harel Gadot在公司全资子公司C&；RD Israel Ltd.与Microbot Medical Ltd.合并并并入Microbot Israel&；后成为该公司总裁、首席执行官和董事会主席，Microbot Israel作为公司的全资子公司幸存（The“；Merger”；）。Gadot先生是Microbot Israel的联合创始人，自Microbot Israel于2010年11月成立以来一直担任Microbot Israel的首席执行官。他自2014年7月起担任Microbot Israel’；的董事会主席。他还担任XACT Robotics Ltd.的董事长，该公司是一家总部位于以色列的私营公司，寻求在微创介入程序（如活检和消融）中开发机器人针头转向的新型平台技术，自2013年8月和Medx Xelerator L.P.，医疗设备和数字健康以色列孵化器，自2016年7月起。从2007年12月到2010年4月，他曾担任Ethicon公司（强生公司）的全球集团营销董事，在那里他曾负责公司的全球战略营销。Gadot先生还在强生公司（Johnson and Johnson）担任管理职位，以及欧洲，中东和非洲以及以色列的领导区域战略职位。从2010年8月到2013年11月Contipi Ltd.被金佰利公司收购，Gadot先生担任Contipi Ltd.的董事。Gadot先生拥有纽约州Loudonville Siena College的商业学士学位和英国曼彻斯特大学（University of Manchester，UK）的工商管理硕士学位。
- Harel Gadot is a co founder of Microbot Israel and has served as Microbot Israel's Chief Executive Officer since Microbot Israel was founded in November 2010. He also serves as a director from September 2025 of Brenmiller Energy (NASDAQ: BNRG). He has been the Chairman of Microbot Israel's board of directors since July 2014. He also served as a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel, and was its Chairman from Augt 2013 until September 2023. Mr. Gadot served as Chairman of MEDX Xelerator L.P., a medical device and digital health Israeli incubator, from July 2016 until Augt 2025. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the Company. Mr. Gadot also held management positions, as ll as leading regional strategic position for Europe, Middle East and Africa, as ll as In Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from Augt 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly Clark Corporation. Mr. Gadot holds a B.Sc. in Biness from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK.
- Simon Sharon
Simon Sharon自2018年4月起担任公司首席技术官，自2021年4月起担任Microbot Israel总经理。从2016年8月到2018年3月，Sharon先生担任Medx Xelerator的首席技术官，这是一家以色列医疗设备和数字健康孵化器。他也是Xact Robotics Ltd.的董事，该公司是一家以色列私营公司，开发一种新型平台机器人技术，用于微创介入手术中的指针转向。Harel Gadot先生是公司的总裁、首席执行官和董事长，是Xact和Medx Xelerator的董事长。在此之前，Sharon先生于2013年2月至2016年8月在Microbot Israel成为上市公司之前担任首席运营官。在加入Microbot Israel之前，Sharon先生是Icecure Medical（一家TASE贸易公司，开发低温消融系统的投资组合）的研发副总裁。在加入Icecure之前，他在Rockwell Automation-Anorad Israel Ltd.担任越来越多的职务，这是一家领先的基于线性马达的精密定位设备制造商。在加入Rockwell之前，Sharon先生是Disc-O-Tech Medical Technologies Ltd.的研发经理，Disc-O-Tech Medical Technologies Ltd.是一家私人骨科企业，被Kyphon收购，目前是Medtronic的一部分，在此之前，Sharon先生是CI Systems的研发经理，世界范围内广泛供应各种电光测试和测量设备.
Simon Sharon has served as the Company's Chief Technology Officer since April 2018 and as the General Manager of Microbot Israel since April 2021. From Augt 2016 to March 2018, Mr. Sharon served as the Chief Technology Officer at MEDX Xelerator, an Israel based medical device and digital health incubator. He was also a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel. Mr. Harel Gadot, the Company's President, CEO and Chairman, is the Chairman of MEDX Xelerator. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Israel before it became a publicly traded company from February 2013 to Augt 2016. Prior to joining Microbot Israel, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockll Automation Anorad Israel Ltd., a leading linear motor based, precision positioning equipment manufacturer. Prior to Rockll, Mr. Sharon was the Research & Development Manager at Disc O Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro optical test and measurement equipment.- Simon Sharon自2018年4月起担任公司首席技术官，自2021年4月起担任Microbot Israel总经理。从2016年8月到2018年3月，Sharon先生担任Medx Xelerator的首席技术官，这是一家以色列医疗设备和数字健康孵化器。他也是Xact Robotics Ltd.的董事，该公司是一家以色列私营公司，开发一种新型平台机器人技术，用于微创介入手术中的指针转向。Harel Gadot先生是公司的总裁、首席执行官和董事长，是Xact和Medx Xelerator的董事长。在此之前，Sharon先生于2013年2月至2016年8月在Microbot Israel成为上市公司之前担任首席运营官。在加入Microbot Israel之前，Sharon先生是Icecure Medical（一家TASE贸易公司，开发低温消融系统的投资组合）的研发副总裁。在加入Icecure之前，他在Rockwell Automation-Anorad Israel Ltd.担任越来越多的职务，这是一家领先的基于线性马达的精密定位设备制造商。在加入Rockwell之前，Sharon先生是Disc-O-Tech Medical Technologies Ltd.的研发经理，Disc-O-Tech Medical Technologies Ltd.是一家私人骨科企业，被Kyphon收购，目前是Medtronic的一部分，在此之前，Sharon先生是CI Systems的研发经理，世界范围内广泛供应各种电光测试和测量设备.
- Simon Sharon has served as the Company's Chief Technology Officer since April 2018 and as the General Manager of Microbot Israel since April 2021. From Augt 2016 to March 2018, Mr. Sharon served as the Chief Technology Officer at MEDX Xelerator, an Israel based medical device and digital health incubator. He was also a director until January 2024 of XACT Robotics Ltd., an Israel based private company that recently ceased operations and is in insolvency proceedings in Israel. Mr. Harel Gadot, the Company's President, CEO and Chairman, is the Chairman of MEDX Xelerator. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Israel before it became a publicly traded company from February 2013 to Augt 2016. Prior to joining Microbot Israel, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockll Automation Anorad Israel Ltd., a leading linear motor based, precision positioning equipment manufacturer. Prior to Rockll, Mr. Sharon was the Research & Development Manager at Disc O Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro optical test and measurement equipment.
- Rachel Vaknin
Rachel Vaknin，自2022年4月起担任公司首席财务官，在此之前自2022年1月起担任公司财务副总裁。2017年9月至2021年12月，Vaknin女士担任以色列-美国自主技术软件供应商Imagry的首席财务官。从2004年4月至2016年12月，Vaknin女士担任迈勒罗斯科技有限公司的FP & A部门经理，该公司是一家以色列-美国跨国计算机网络产品供应商，于2020年被英伟达收购。在该公司，除其他外，她负责预算规划、预算控制、建立和维护商业情报关键绩效指标、领导团队编制季度财务报表、获取和管理赠款以及萨班斯-奥克斯利控制。
Rachel Vaknin has served as the Company's Chief Financial Officer since April 2022 and before that was its VP Finance since January 2022. From September 2017 to December 2021, Ms. Vaknin served as the Chief Financial Officer at an Israeli American autonomo technologies software provider. From April 2004 through December 2016, Ms. Vaknin was the FP&A Department Manager at Mellanox Technologies Ltd., an Israeli American multinational supplier of computer networking products acquired by Nvidia in 2020, where she was responsible, among other things, for managing FP&A, leading teams with respect to preparing quarterly financial statements, obtaining and managing grant monies, and Sarbanes Oxley controls.- Rachel Vaknin，自2022年4月起担任公司首席财务官，在此之前自2022年1月起担任公司财务副总裁。2017年9月至2021年12月，Vaknin女士担任以色列-美国自主技术软件供应商Imagry的首席财务官。从2004年4月至2016年12月，Vaknin女士担任迈勒罗斯科技有限公司的FP & A部门经理，该公司是一家以色列-美国跨国计算机网络产品供应商，于2020年被英伟达收购。在该公司，除其他外，她负责预算规划、预算控制、建立和维护商业情报关键绩效指标、领导团队编制季度财务报表、获取和管理赠款以及萨班斯-奥克斯利控制。
- Rachel Vaknin has served as the Company's Chief Financial Officer since April 2022 and before that was its VP Finance since January 2022. From September 2017 to December 2021, Ms. Vaknin served as the Chief Financial Officer at an Israeli American autonomo technologies software provider. From April 2004 through December 2016, Ms. Vaknin was the FP&A Department Manager at Mellanox Technologies Ltd., an Israeli American multinational supplier of computer networking products acquired by Nvidia in 2020, where she was responsible, among other things, for managing FP&A, leading teams with respect to preparing quarterly financial statements, obtaining and managing grant monies, and Sarbanes Oxley controls.
- Juan Diaz Cartelle
Juan Diaz Cartelle自2023年12月1日起担任公司首席医疗官。作为首席营销官，Diaz Cartelle博士将领导公司临床战略的制定和执行，包括其计划在美国进行的LIBERTY血管内机器人手术系统临床试验、医疗事务活动，并将成为领导其与FDA的监管程序和商业努力的团队的组成部分。最近，从2022年5月到2023年11月，Diaz Cartelle博士在Haemonetics Corporation（纽约证券交易所代码：HAE）担任执行医疗总监，在那里他就心血管领域的新投资为该公司提供建议，以及其他职责。在此之前，从2008年6月到2022年5月，Diaz Cartelle博士在波士顿科学国际有限公司（NYSE：BSX）担任外周介入部门（血管内和介入肿瘤学）的高级医疗总监，在那里他在制定全球临床战略和研究监督、支持商业活动和未来管道开发方面发挥了关键作用。Diaz Cartelle博士在纳瓦拉大学（西班牙）获得医学学位，并在马德里综合大学Gregorio Maranon医院（西班牙）完成了他作为血管学家和血管外科医生的专业。
Juan Diaz Cartelle has served as the Company's Chief Medical Officer since December 1, 2023. As CMO, Dr. Diaz Cartelle will lead the development and execution of the clinical strategy of the Company, including its planned clinical trials for the LIBERTY Endovascular Robotic Surgical System in the U.S., the medical affairs activity, and will be an integral part of the team leading its regulatory process with the FDA and commercial efforts. Most recently, from May 2022 to November 2023, Dr. Diaz Cartelle served as the Executive Medical Director at Haemonetics Corporation (NYSE: HAE), where he advised that company on new investments in the cardiovascular space, among other responsibilities. Prior to that, from June 2008 to May 2022, Dr. Diaz Cartelle served as the Senior Medical Director for the Peripheral Interventional Division (Endovascular and Interventional Oncology) at Boston Scientific Corporation (NYSE: BSX), where he played a pivotal part in the development of global clinical strategy and study oversight, supporting commercial activities and future pipeline development. Dr. Diaz Cartelle obtained his medical degree at the University of Navarra (Spain) and completed his specialty as Angiologist and Vascular Surgeon at Hospital General Universitario Gregorio Maranon in Madrid (Spain).- Juan Diaz Cartelle自2023年12月1日起担任公司首席医疗官。作为首席营销官，Diaz Cartelle博士将领导公司临床战略的制定和执行，包括其计划在美国进行的LIBERTY血管内机器人手术系统临床试验、医疗事务活动，并将成为领导其与FDA的监管程序和商业努力的团队的组成部分。最近，从2022年5月到2023年11月，Diaz Cartelle博士在Haemonetics Corporation（纽约证券交易所代码：HAE）担任执行医疗总监，在那里他就心血管领域的新投资为该公司提供建议，以及其他职责。在此之前，从2008年6月到2022年5月，Diaz Cartelle博士在波士顿科学国际有限公司（NYSE：BSX）担任外周介入部门（血管内和介入肿瘤学）的高级医疗总监，在那里他在制定全球临床战略和研究监督、支持商业活动和未来管道开发方面发挥了关键作用。Diaz Cartelle博士在纳瓦拉大学（西班牙）获得医学学位，并在马德里综合大学Gregorio Maranon医院（西班牙）完成了他作为血管学家和血管外科医生的专业。
- Juan Diaz Cartelle has served as the Company's Chief Medical Officer since December 1, 2023. As CMO, Dr. Diaz Cartelle will lead the development and execution of the clinical strategy of the Company, including its planned clinical trials for the LIBERTY Endovascular Robotic Surgical System in the U.S., the medical affairs activity, and will be an integral part of the team leading its regulatory process with the FDA and commercial efforts. Most recently, from May 2022 to November 2023, Dr. Diaz Cartelle served as the Executive Medical Director at Haemonetics Corporation (NYSE: HAE), where he advised that company on new investments in the cardiovascular space, among other responsibilities. Prior to that, from June 2008 to May 2022, Dr. Diaz Cartelle served as the Senior Medical Director for the Peripheral Interventional Division (Endovascular and Interventional Oncology) at Boston Scientific Corporation (NYSE: BSX), where he played a pivotal part in the development of global clinical strategy and study oversight, supporting commercial activities and future pipeline development. Dr. Diaz Cartelle obtained his medical degree at the University of Navarra (Spain) and completed his specialty as Angiologist and Vascular Surgeon at Hospital General Universitario Gregorio Maranon in Madrid (Spain).